Table 3. New drug formulations for ALL therapy.
| Drug | Benefits |
|---|---|
| Pegylated asparaginase | Long half-life, reduced immunogenicity (24) |
| Liposomal daunorubicin | Decreased cardiotoxicity (25) |
| Liposomal annamycin | Decreased cardiotoxicity (NCT00430443) |
| Sphingosomal vincristine | Decreased neuropathy, high tissue concentration, non-vesicant (26) |
| Liposomal cytarabine | Long half-life (27) (NCT00002704, NCT00991744) |